华泰联合证券有限责任公司 关于浙江九洲药业股份有限公司 2024 年持续督导年度报告书 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：浙江九洲药业股份有限公 | | --- | --- | | | 司 | | 保荐代表人姓名：沈钟杰 | 联系电话：025-83387713 | | 保荐代表人姓名：唐澍 | 联系电话：025-83387726 | 根据《证券法》、《证券发行上市保荐业务管理办法》、《上海证券交易所 股票上市规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督 导》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简称"华泰联 合证券"或"保荐机构"）作为浙江九洲药业股份有限公司（以下简称"九洲药 业"、"公司"或"发行人"）2022 年非公开发行股票的保荐机构，对九洲药 业进行持续督导。现就 2024 年度持续督导工作总结如下： 一、持续督导工作情况 | 序号 | 工作内容 | 完成持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并 | 保荐机构已制定并严格执行持续督导 | | | 针对具体的持续督导工 ...

关于浙江九洲药业股份有限公司 2022 年非公开发行 A 股股票 之保荐总结报告书 保荐机构名称 华泰联合证券有限责任公司 保荐机构编号 Z26774000 华泰联合证券有限责任公司 四、保荐工作概述 | 项目 | 工作内容 | | | | --- | --- | --- | --- | | 1、尽职推荐工作 | 按照相关法律法规要求，对发行人情况进行尽职调查，组织 | | | | | 编制申请文件并出具推荐文件；提交推荐文件后，主动配合中国 | | | | | 证监会的审核，组织发行人及其它中介机构对中国证监会的意见 | | | | | 进行答复，按照中国证监会的要求对涉及本次证券发行上市的特 | | | | | 定事项进行尽职调查或核查，并与中国证监会进行专业沟通，按 | | | | | 照证券交易所上市规则的要求向证券交易所提交推荐股票上市要 | | | | | 求的相关文件，并报中国证监会备案。 | | | | 2、持续督导期间 | | | | | （1）公司信息披露审阅 | 持续督导期的信息披露文件由我公司保荐代表人事前审阅或 | | | | 情况 | 及时事后审阅。 | | | | （2）现场检查 ...

Core Viewpoint - The company reported a steady growth in revenue and net profit for Q1 2025, driven by the increasing orders in its CDMO business and enhanced R&D capabilities [1] Financial Performance - In Q1 2025, the company achieved revenue of 1.49 billion yuan, a year-on-year increase of 0.98% - The net profit attributable to shareholders was 250 million yuan, up 5.68% year-on-year - The non-recurring net profit was 251 million yuan, reflecting a year-on-year growth of 7.17% [1] - The gross margin improved to 37.42%, an increase of 3.38 percentage points year-on-year and 6.84 percentage points quarter-on-quarter - The net profit margin was 16.77%, up 0.77 percentage points year-on-year and 18.93 percentage points quarter-on-quarter - The operating expense ratio was 13.52%, an increase of 1.70 percentage points year-on-year but a decrease of 2.49 percentage points quarter-on-quarter [2] CDMO Business Development - The company is a leading CDMO provider, offering comprehensive services for pharmaceutical companies, biotech firms, and research institutions - It specializes in small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs - The company has received recognition for its CDMO marketing system project at the 6th National Pharmaceutical Health CIO Conference, winning the "2025 National Pharmaceutical Health Digital Excellence Case" award [3] Investment Outlook - Revenue projections for 2025-2027 are 5.803 billion, 6.151 billion, and 6.315 billion yuan, with growth rates of 12.45%, 6.01%, and 2.65% respectively - Net profit forecasts for the same period are 830 million, 929 million, and 991 million yuan, with growth rates of 36.89%, 11.99%, and 6.60% - Earnings per share (EPS) are expected to be 0.93, 1.04, and 1.11 yuan per share, with a 3-year CAGR of 17.79% - The company maintains a "buy" rating due to its comprehensive CDMO business layout and leading technological strength [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603456 证券简称：九洲药业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 单位：元 币种：人民币 ■ 公司是一家技术驱动的行业领先CDMO企业，致力于为全球制药公司、生物科技公司、科研机构等提供 一站式的医药定制研发和生产（CDMO）服务，包含小分子化学药物、多肽药物、偶联药物和小核酸药 物。公司始终秉承"关爱生命、维护健康、成为全球药物创新解决方案的卓越生命健康企业"的使命愿景 和可持续发展理念，凭借深耕行业多年积累的深厚行业洞察力、成熟研发生产能力以及良好客户声誉， 恪守国际质量监管标准，以高效的交付效率、贴心的客户服务为宗旨，支持全球客户的药物开发。 2025年一季度公司实现归属于上市公 ...

Group 1: Macroeconomic Insights - In March 2025, exports increased significantly with a year-on-year growth rate of 12.4%, up from 2.3% in January-February, surpassing Bloomberg's consensus estimate of 4.6% [2] - The trade surplus for March reached $102.6 billion, contributing to a cumulative trade surplus of nearly 2 trillion RMB in the first quarter, which is an increase of approximately 600 billion RMB year-on-year [2] - The estimated contribution of external demand to actual GDP growth is projected to be 2.9 percentage points, potentially pushing the actual GDP year-on-year growth rate to 5% or higher [2] Group 2: Market Trends and Fund Flows - In the A-share market, there was a net outflow of financing funds close to 100 billion RMB last week, but the financing balance stabilized in the latter half of the week, indicating a potential market reversal [3] - The week saw significant inflows into broad-based ETFs, with net inflows reaching a record high since 2018, driven by institutional announcements of increased holdings [3] - The scale of share buybacks and capital increases reached new highs for 2025, indicating strong support for market stabilization [3] Group 3: Real Estate Sector Analysis - In 2024, the overall performance of domestic real estate companies was under pressure, with declines in both sales and land acquisition amounts, but the industry concentration increased, showing resilience among leading firms [12] - The main theme for 2025 is expected to be "steady operation and focus on core business," with a strategy of "sales-driven investment" to revitalize old inventory [12] - There is an anticipated increase in the proportion of operating profits for some real estate companies, alongside a continuous push for product quality upgrades [12] Group 4: Lithium Battery Materials Outlook - In 2024, capital expenditures for most lithium battery material companies declined year-on-year, with significant changes in supply-demand dynamics and profitability [13] - The report forecasts a tightening supply-demand situation for lithium iron phosphate and lithium hexafluorophosphate in the second half of 2025, leading to potential price increases [13] - Companies with cost or technological advantages in the supply chain are expected to see improvements in market share and profitability [13] Group 5: Company-Specific Performance - Shanghai Construction Group reported a revenue of 300.2 billion RMB for 2024, a slight decline of 1.45% year-on-year, but net profit increased by 39.2% [14] - Net profit for Guoyuan Securities reached 2.244 billion RMB in 2024, a year-on-year increase of 20%, driven by a 123% increase in investment income [15] - Net profit for NetEase Technology in 2024 was 675 million RMB, reflecting a 10.02% year-on-year increase, with expectations for accelerated growth in 2025 due to AI applications [15]

Group 1: Zhongjuxin - In 2024, Zhongjuxin's revenue will primarily come from the integrated circuit sector, accounting for nearly 74% of total revenue, with a slow recovery in semiconductor market demand [1] - The photovoltaic industry is experiencing negative gross margins, and the company will focus on integrated circuit clients in the future [1] - Electronic specialty gases generated revenue of 247 million yuan with a gross margin of 20.70%, mainly from high-purity chlorine [1] - The second phase of electronic specialty gases products will enhance gross margins, while the electronic wet chemical segment is facing declining margins due to industry competition [1] - The company reported a loss in Q4 due to increased labor costs, R&D investments, and year-end project expenses [1] - Overseas sales revenue is approximately 90 million yuan, with sales to the U.S. accounting for less than 1% of total revenue, indicating limited impact [1] - The company plans to expand market efforts and overseas sales channels in 2025 [1] Group 2: Jiuzhou Pharmaceutical - Jiuzhou Pharmaceutical indicated that the suspension of the PLI plan in India benefits raw material drug manufacturers in other countries, with domestic raw material prices stabilizing [2] - The CDMO business is expected to see a 15% year-on-year increase in new projects and a 20% increase in contract value in 2024, with revenue nearing 3.9 billion yuan and nearly 80% from overseas clients [2] - The company anticipates a recovery of CDMO gross margins to around 40% by 2025 [2] - In Q1, the overall capacity utilization rate was approximately 60%, with capital expenditures planned to be controlled at 500-600 million yuan in 2025 [2] - The company aims to introduce leading talents in the fields of peptides, DC, and small nucleic acids over the next three years [2] - Jiuzhou Pharmaceutical plans to provide services to over 70 clients in 2024, with nearly 30 new clients onboarded, focusing on inhalation formulations and liposome technology platforms [2]

Group 1: Jiuzhou Pharmaceutical - Jiuzhou Pharmaceutical indicated that the suspension of the PLI plan in India benefits raw material manufacturers in other countries, with domestic raw material prices gradually stabilizing [1] - The number of new CDMO projects in 2024 is expected to grow by 15% year-on-year, with contract amounts increasing by 20% [1] - CDMO business revenue is close to 3.9 billion yuan, with nearly 80% coming from overseas, primarily from European clients [1] - The company anticipates a recovery in CDMO gross margin to around 40% by 2025 [1] - In Q1, the overall capacity utilization rate was approximately 60%, with capital expenditures for 2025 controlled at 500-600 million yuan [1] - The second phase of the commercial production capacity for the peptide department is expected to be operational by September 2025 [1] Group 2: Lanke Technology - Lanke Technology plans to focus on the development of computing power chips for intelligent hardware over the next 5-10 years, emphasizing the importance of interconnect chips [2] - The demand for DDR5 memory interface chips is expected to significantly increase due to trends in the AI industry [2] - The company has invested in the development of PCIe Switch chips and anticipates continued growth in demand for PCIe Retimer chips, primarily driven by AI server shipments [2] - Lanke Technology's core business maintains high quality, with major products being high value-added, resulting in a high gross margin [2] - The company has linked the market value to executive performance evaluations for three consecutive years to align management interests with shareholder interests [2]

Group 1 - The US government has temporarily exempted certain electronic products from tariffs, but this exemption is not permanent and will last only until a new tariff plan for the semiconductor industry is established [2][21] - China's foreign trade in the first quarter of this year reached 10.3 trillion yuan, a year-on-year increase of 1.3%, with exports growing by 6.9% and imports declining by 6% [3] - The State Administration for Market Regulation in China has introduced 37 key measures to support the development of private enterprises, focusing on breaking down barriers and promoting fair competition [4][5] Group 2 - Hong Kong is preparing to attract Chinese concept stocks back to its market, emphasizing its stability and attractiveness amid global financial market volatility [6][7] - The China Securities Regulatory Commission has emphasized the importance of functionality in the fund industry, aiming for a balance between quality and scale [8] - Insurance funds are accelerating their entry into the stock market, with the scale of long-term stock investment trials increasing from 50 billion yuan to 162 billion yuan [9] Group 3 - The US is experiencing a significant drop in import orders, with a 64% decrease in overall import volume, indicating potential disruptions in trade due to tariff policies [10][11] - The total share of stock ETFs in A-shares has surpassed 2 trillion shares, marking a historical high, with substantial inflows of capital observed in April [12] - Global pension funds are pausing investments in US assets due to uncertainties stemming from aggressive tariff policies, indicating a shift in investment strategies [13] Group 4 - The AI industry is facing scrutiny over its energy consumption, with Elon Musk's AI company xAI being investigated for violating environmental regulations related to its power generation [14] - The UK government plans to take over the British Steel Company from a Chinese firm, raising concerns about foreign investments in critical industries [15] - The consumer electronics sector is seeing increased research interest, driven by strong domestic demand policies and a surge in M&A activities in the technology field [17]

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

浙江九洲药业股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 22 日（星期二）15:00-16:00 会议召开方式：上证路演中心视频录播和网络互动 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 投资者可于 2025 年 4 月 15 日（星期二）至 4 月 21 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhoupharma.com）进行提问，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 一、说明会类型 证券代码：603456 证券简称：九洲药业 公告编号：2025-024 三、公司参加人员 董事兼总裁梅义将先生；董事、执行副总裁兼财务负责人沙裕杰先生；独立 董事蒋琦女士；董事、执行副总裁兼董事会秘书林 ...